
    
      This is a multicentre, randomized, double-blind, parallel group, placebo-controlled, phase 2
      study to designed evaluate the effect of a 300 mg dose of tralokinumab administered
      subcutaneously every 2 weeks on airway inflammation in adults with asthma inadequately
      controlled on inhaled corticosteroids (ICS) with or without other controllers. Approximately
      80 subjects will be randomized. Subjects will receive tralokinumab, or placebo, administered
      via subcutaneous injection at the study site, over a 12 week treatment period.
    
  